EUnetHTA Plenary Assembly

April 10-11, 2014

Madrid, Spain

Mid-term EUnetHTA strategic development (JA3 – (2016-2020)

Juergen Hohmann, rapporteur of the green WG

1. Achievements in JA3?

Prioritize outputs

- **Better linking international production and national uptake**
  - Enhancing the national implementation of guidelines
- **Making countries/national partners more accountable**
  - Setting benchmarking and apply peer-review processes
- **Closing the gap between countries/agencies of different levels of HTA performance**
  - Formation of country clusters based on level of commitments and activity priorities
- **Better advocating HTA**
  - Intensify marketing from scientific level
  - Develop a communication plan for HTA production

Leverage synergies

- between national and international level
- between strategic and scientific/technical level

2. What will define priorities of specific activities for JA3?

- **An extensive stock-taking exercise should allow identifying activities with highest potential for collaboration**
  - only these should be continued

- **The commitment to apply HTA to a whole range of health technologies should be reflected by**
  - Addressing 1-2 large non-pharmaceutical issues by joint pilot production
    - The selection can be done on strategic level
      - High potentials: ICT-enabled programs, prevention, surgical procedures
    - The scientific level will perform the assessment
    - Context specific dimensions should be given utmost attention

3. Overcome limitations

- **Better Identify limitations with the help of an independent HTA auditor**
  - To assess national usage, legal restrictions and diversity of HTA products
  - A report of the results should be made available by 2016
  - Only EUnetHTA products with highest potential of collaboration should be continued
- **Professionalize the process of HTA production**
  - Supplement the voluntariness with objective criteria of required technical capacities
  - Each topic should undergo a separate tender process
  - The EMA Committee for Medicinal Products for Human Use (CHMP) serves as example of good practice
- **Implement more flexible measures of collaboration**
  - Ad hoc «enhanced collaboration» by a number of members
  - It requires a budget line to support such work
  - JA3 may also provide possibiities of sub-contracting

4. Modes of operation

- **The different levels of collaboration should be continued**
  - 1: Sharing and exchange of information
  - 2: Development of common generic guidelines
  - 3: Application of standards and tool at national/regional level

  - The commitments, however, should me made more specific
  - And countries need to be made accountable to perform accordingly

5. Relation between HTAN and scientific and technical cooperation

- **Building and leveraging synergies**
  - EUnetHTA acts as scientific partner to HTAN
  - Strengthen relationships between national agencies and representatives in HTAN



6. Which processes of JA2 should be further improved

- **Topic selection**
  - WP5 – Dependency of manufacture interest interferes with the topic selection according to needs
  - Obsolete technologies could be taken into account

- **Stakeholder involvement**
  - Appropriateness of the stakeholder forum to be reconsidered
  - Better involvement of stakeholders in all WPs

- **Guidelines development**
  - Implement processes for revision and development

- **Training activities**
  - Find a good balance between f-t-f and e-learning training activities